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Abstract 
Purpose: To investigate the relationship between miR-499 rs3746444 and miR-196a rs11614913 
polymorphisms, and susceptibility to breast cancer in an Iranian population.   
Methods: This case-control study was performed on a population of 200 subjects comprising 100 
breast cancer patients (case/observation group) and 100 healthy individuals (control group). 
Amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) was used to genotype 
these polymorphisms. P-values and odd ratios were determined, and p-values < 0.05 and odd ratios > 1 
were considered statistically significant.  
Results: There were no significant differences between observation and control groups with respect to 
rs11614913 T/C polymorphism. The rs11614913 T allele was not identified as a risk factor for 
susceptibility to breast cancer (OR = 0.86, 95 % CI = 0.85 - 1.3, p = 0.46). However, there were 
significant differences between observation and control groups with respect to rs3746444 T/C 
polymorphism. It was observed that cytosine-cytosine (CC) (OR = 4.5, 95 % CI = 1.3 - 15.4, p = 0.06), 
and cytosine-thymine (CT) (OR = 1.9, 95% CI = 1- 3.6, p = 0.04) genotypes had protective influence 
against susceptibility to breast cancer. 
Conclusion: These results indicate that CC and CT genotypes are associated with reduced risk of 
breast cancer. In particular, the presence of C allele is significantly associated with a low risk of breast 
cancer. These findings may provide useful information for prevention and early diagnosis of breast 
cancer. 
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Breast cancer is the most common malignancy 
among women: about one million new patients 
are added annually to the world population of 
female breast cancer patients. This cancer 
accounts for 10 % of all cancers and 23 % of 
female cancers in developed countries [1].  
 
There are more than 1000 microRNA (miRNA) 
genes in the human genome which regulate the 
translation or degradation of human messenger 
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RNA (mRNA) by a complement sequence. 
Genetic variations in a miRNA may affect its 
maturation and biogenesis, and these are linked 
to the pathogenesis of a lot of diseases, which 
include breast cancer [2]. Researchers have 
shown that genetic polymorphisms are one of the 
main causes of individual differences in cancer 
prevalence. Single nucleotide polymorphisms 
(SNPs) in miRNAs can be used as genetic 
markers for prognosis breast cancer 
susceptibility or prediction [3]. 
 
Several miRNAs are abnormally expressed in 
breast cancer tissue when compared with normal 
breast tissue. These include miR-196a and miR-
499. Indeed, miR-196a is exceedingly expressed 
in breast cancer tissue [4]. Moreover, several 
studies have recognized genetic variants in the 
precursor miRNA sequence of miR-499 
rs3746444 as possible biomarkers related to the 
etiology of breast cancer [5]. 
 
There are a few molecular and epidemiological 
studies on the association between breast 
cancer and polymorphisms in miR-499 
rs3746444 and miR-196a rs11614913 [6].  
 
To the best of our knowledge, there are no 
reports on the association between miR-196a 
rs11614913 and miR-499 rs3746444 
polymorphisms, and the risk of breast cancer in 
an Iranian population.  
 
In order to investigate if such association exist, a 
hospital-based case-control study on an Iranian 
population was carried out in this study, based 
on genotyping analysis applying amplification 
refractory mutation system-polymerase chain 






Whole blood samples were collected from 
healthy females and females with breast cancer 
in the teaching hospital of Mashhad University of 
Medical Sciences, Iran. A total of 100 control 
samples were chosen from different ages (18 – 
61), while 100 breast cancer cases were 
selected from female patients aged 45 – 64 
years. Each patient included in the study gave 
informed consent. The study protocol conformed 
with the ethical codes of the 1975 Declaration of 
Helsinki [7], and was approved by the local 
Research and Medical Ethics Committee 
(approval ref. no. IR.IAU.5106930121003). All 
samples were collected in the hospital according 
to Iranian medical ethics. 
 
DNA isolation and amplification 
 
A 5-mL sample of peripheral whole blood was 
collected from each subject into an EDTA 
anticoagulant tube. Genomic DNA was extracted 
using High Pure PCR Template Preparation Kit 
(Roche Diagnostics, GmbH, Mannheim, 
Germany) according to the manufacturer’s 
protocol. The miR-196a and miR-499 gene SNPs 
were analyzed using ARMS-PCR. In this method, 
three primers were used to amplify the 
rs11614913 and rs3746444 SNPs (Table I). The 
PCR reactions were prepared using Taq DNA 
Polymerase (Ampliqon, Denmark) according to 
the manufacturer’s manual. The conditions of 
PCR were: initial denaturation at 95 °C for 5 min, 
33 cycles of denaturation (95 °C for 30 s), 
annealing (60 °C for 30 s), extension (72 °C for 
40 s), and a final extension step (72 °C for 10 
min). The PCR products were mixed by power 
load stain and ran in a 1 % agarose gel. 
 
Table 1: Primer sequences for the detection of mir-
146a and miR-499 gene polymorphisms 
 


















To examine the differences in allele frequencies, 
chi-square (χ2) analysis was used and the 
distribution of genotypes between case and 
control samples was calculated using (SPSS v. 
22). The association between genotype and risk 
of breast cancer was evaluated by calculating the 
odds ratio (OR) and their 95 % confidence 
intervals (95 % CI) with logistic regression 
models. All statistical tests were two-sided. 
Values of OR > 1, and p values < 0.05 were 
considered statistically meaningful, indicating the 





The frequency distribution of miR-196a 
rs11614913 T/C genotypes in breast cancer 
patients and normal subjects is presented in 
Table 2. There were no significant differences in 
rs11614913 T/C polymorphism between the 
breast cancer patients and controls. Thus, miR-
196a rs11614913 T/C polymorphism was not 
identified as a risk/protection factor for 
susceptibility to breast cancer. In addition, the 
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rs11614913 T allele was not identified as a risk 
factor for susceptibility to breast cancer (OR = 
0.86, 95 % CI = 0.85- 1.3, p = 0.46). 
 
The frequency distributions of miR-499 
rs3746444 T/C genotypes in breast cancer 
patients and normal subjects are presented in 
Table 3. There were significant differences 
between the breast cancer group and the control 
group samples with respect to genotypes or 
alleles according to the (χ2) analysis of data. The 
CC (OR = 4.5, 95% CI = 1.3- 15.4, p = 0.06) and 
CT (OR = 1.9, 95% CI = 1- 3.6, p = 0.04) 
genotypes had protective effect on breast 
cancer. In addition, individuals with C allele 
presented a low risk for breast cancer 
development (OR = 2.03, 95% CI = 1.3-3.3, p = 
0.003).  
 
Table 2: Genotype and allele frequencies of 
rs11614913 (C/T) polymorphism for breast cancer 








- 1 (reference) 25(25) 33(33.7) CC 
0.15 0.62(0.33 - 
1.18) 
62(62) 51(52) CT 
0.66 0.82(0.33 - 
2) 
13(13) 14(14.3) TT 
 Allele 
- 1(reference) 112(56) 117(60) C 
0.46 0.86(0.58 - 
1.3) 
88(44) 79(40) T 
 
Table 3: Genotype and allele frequencies of 
rs3746444 (T/C) polymorphism for breast cancer 







TT 35(43.8) 63(63) 1 
(reference) 
- 
CT 35(43.8) 33(33) 1.9 (1 - 3.6) 0.04 




T 105(66) 159(79.5) 1 
(reference) 
- 






The present research was conducted to assess 
the association between polymorphisms in miR-
499 rs3746444 and miR-196a rs11614913, and 
breast cancer development, in view of absence 
of such studies in an Iranian population [8]. 
Numerous associations between miRNAs and 
incidence of breast cancer have been 
demonstrated experimentally. An understanding 
of the mechanisms involved in these 
associations is crucial for the use of miRNAs 
markers as strong tools for the blockage and 
treatment of breast cancer [9].   
 
The miRNAs are involved in several critical 
biological processes such as development, 
proliferation, differentiation and apoptosis. 
Genetic polymorphisms in miRNAs (SNPs) can 
potentially affect the selection or processing of 
miRNA targets. Several recent studies have 
assessed the association between SNPs in miR-
196a rs11614913 and miR-499 rs37464, and 
susceptibility to breast cancer [5, 10]. In view of 
the important roles of miR-499 rs3746444 and 
miR-196a rs11614913 in the etiology of breast 
cancer, the present study evaluated the 
distribution of these genotypes and assessed the 
risk of breast cancer development in Iranian 
women. 
 
The results obtained indicate that rs11614913 
polymorphism is not associated with an 
increased risk of breast cancer in this case-
control study in Iranian women.  This is in 
agreement with the results obtained by Jedlinski 
et al who reported that there was no relation 
between rs11614913 polymorphism and breast 
cancer in Caucasian case-control cohort in 
Queensland, Australia [11]. Similarly, a study 
conducted on a Brazilian female population 
found no relation between rs11614913 
polymorphism and breast cancer [12]. In 
addition, Catucci et al reported that there was no 
statistical correlation between the existence of 
miR-196a rs11614913 in women affected by 
breast cancer and controls in German and Italian 
populations [8]. However, the results obtained in 
the present study are at variance with those 
reported by Hu et al and Hoffman et al who 
established an association between rs11614913 
and the risk of breast cancer. Some population-
specific factors, such as differences in genetic 
background, environmental factors, or lifestyle 
might explain these discrepancies in relation 
between rs11614913 polymorphism and breast 
cancer [10,13].  
 
Many case-control studies have explored the 
relation between SNP in miR-499 and risk of 
different kinds of cancer [14]. Polymorphism in 
miR-499 rs3746444 has been shown to be 
distinctly correlated with a variety of diseases, 
including breast cancer [10,15]. Yet, only a few 
epidemiological studies have focused on the 
association between miR-499 rs3746444 
polymorphisms and risk of breast cancer. 
 
In the present study, the association between 
miR-499 rs3746444 polymorphism and breast 
cancer risk was investigated. The results indicate 
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an association between rs3746444 
polymorphism and breast cancer susceptibility. In 
addition, CC and CT genotypes were associated 
with a protective effect against breast cancer. 
Furthermore, women with C allele had a low risk 
for breast cancer development. Consistent with 
these findings, a significant association has been 
demonstrated between rs3746444 polymorphism 
and breast cancer risk in an Asian population [5]. 
Moreover, Xu et al reported breast cancer risk 
among a Chinese population with respect to 
rs3746444 polymorphism [16]. A recent research 
by Sun et al also showed a statistically significant 
association between miRNA-499 rs3746444 
polymorphism and cancer susceptibility in 
Asians, but not in Caucasian population [17]. 
 
Although the results of this study did not suggest 
any association between rs11614913 in miR-
196a and risk of breast cancer, there are some 
evidence that miR-196a may play a major role in 
carcinogenesis. Among the possible targets of 
miR-196a are genes that take part in various 
cancer-related pathways. The split of HOX gene 
products similar to HOXB8 mRNA has been 
shown to be relatively due to miR-196a.  
 
The HOX genes regulate a number of genes 
that, in turn, regulate huge networks of 
alternative genes. Thus, they are involved in 
some key biological processes. Furthermore, the 
potential targets of miR-196a are LSP1 and 
TOX3, which are new breast cancer susceptibility 
genes recently identified in a whole-genome 
association research. It is probable that the 
rs11614913 SNP modulates the acts of these 
two genes in breast cancer progress. However, 
this is yet to be established [18].  
 
Limitations of the study 
 
It was not possible to investigate precisely-
established risk factors (age at menopause, age 
at menarche, hormone replacement therapy, and 





The findings of this study indicate that SNP in 
miR-499 rs3746444 plays a pivotal role in the 
development of breast cancer in the Iranian 
population investigated. However, there is no 
significant association between miR-196a 
rs11614913 SNP and breast cancer 
susceptibility. However, well-designed studies 
involving larger population samples are required 
to establish more firmly the associations of these 
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